TransCode Therapeutics is a biopharmaceutical company that develops and sells drugs and diagnostics to treat and detect metastatic disease. Their main product candidate is TTX-MC138, which is in the preclinical stage of development for treating metastatic cancer. The company also has other preclinical programs and cancer agnostic programs, including RNA-based therapies and mRNA-based cancer vaccines.